This document provides an overview of various multinational pharmaceutical companies and their products and positioning in diabetes treatment. It summarizes information on major companies like Sanofi, Novo Nordisk, Johnson & Johnson, Pfizer, GlaxoSmithKline, and their diabetes products. It also discusses competitors in key markets like the US, Brazil, Germany, India, Australia and Japan. Major diabetes drugs mentioned include Lantus, Apidra, Januvia, Exubera and various oral medications for type 1 and type 2 diabetes.

1. AMARJIT SINGH ID No. MHS1007002

2. INTRODUCTIONMultinational Pharmaceuticals Company.World’s 4th Largest.Founded in 20 August 2004.Head Quarter- Paris, France.

3. INTRODUCTIONCE0 - Chris ViehbacherCHAIRMAN - Jean Francois DehecqREVENUE - € 29.31 billion (2009)PROFIT - € 5.265 billion (2009)

4. INTRODUCTIONIt is a Member of- European Federation of Pharmaceutical Industries & Associations (EFPIA).

5. GENERAL INFORMATIONRevenue - €29.31billion (2009)Operating Income - €6.366billion (2009)Profit - €5.265billion (2009)Market Share - 4.3%Employees - 104,870 (2009)

6. WHAT BUSINESS ARE THEY INManufacturing & Marketing of Pharmaceutical Products.Over the Counter Medication.Research & Development.

7. MAJOR THERAPEUTIC AREAS7 major therapeutic areas- Cardiovascular

8. Central Nervous System

9. Diabetes

10. Internal Medicine

11. Oncology

12. Thrombosis

13. Vaccines (World’s largest producer)POSITIONING OF DIABETES MEDICINEApidra and Lantus are main products.APIDRA- -Rapid-acting. -Works fast.-Used in children 4 years and older with type 1 diabetes.-Adults with type 1 or type 2 diabetes.

14. POSITIONINGLANTUSAdult and pediatric patients with type 1 diabetes mellitus .Adult patients with type 2 diabetesmellitus

15. TOP PHARMACEUTICAL COMPANIES WITH REVENUES AS PER 2009 ANNUAL REPORTJohnson & Johnson (U.S.) - $ 6,190Pfizer (U.S.) - $ 5,001Roche (Switzerland) - $4,735Glaxo Smith Kline (U.K.) - $4,583Novartis (Switzerland) - $4,427Sanofi Aventis (France) - $4,199

16. MARKET SHARE OF DIFFERENT COMPANIES

17. MAJOR COMPETITORS IN U.S.A.Johnson & JohnsonPfizerGlaxo Smith KlineBristol-Myers SquibbAstra Zeneca

18. BRISTOL-MYERS SQUIBB Founded in - 1989Revenue - $18.8 billion(2009)Operating Income - $5.34 billion(2009)Employee’s - 28,000 (2009)

19. MAIN PRODUCTIONS AREAS INCLUDECancerHIV/AIDS Cardiovascular disease Diabetes Hepatitis Rheumatoid Arthritis & Psychiatric disorders.

20. DISTRIBUTION ALL OVER THE WORLD

21. POSITIONING OF MEDICINE FOR DIABETES ONGLYZA™ (saxagliptin) is the main product for diabetes.Developed and marketed through a collaboration with AstraZeneca.For the treatment of type 2 diabetes in adults.

22. JOHNSON & JOHNSONFounded in - 1886Revenue - $61.9 billion(2009)Operating Income - $15.7 billion(2009)Employee’s - 118,700 (2009)

23. MAIN PRODUCTIONS AREAS INCLUDEMedical devicesHealth care products Toiletries Soaps Shampoos

24. POSITIONING OF MEDICINE FOR DIABETES CANAGLIFLOZIN is the main Product.For Oral Type 2 diabetes. Promote Weight Loss in Treatment of Type 2 Diabetes.

25. PFIZERFounded in - 1849Revenue - $50.0 billion(2009)Net Income - $8.63 billion(2009)Employee’s - 116,500 (2009)Ranked No. 2 in sales

26. MAIN PRODUCTIONS AREAS INCLUDELipitor( to lower blood cholesterol)Lyrica(neuropathic drug) Diflucan(the oral antifungal) Antibiotic Zithromax.

27. POSITIONING OF MEDICINE FOR DIABETES EXUBERA for diabetes and Insulin TherapiesExubera is an Inhaled Insulin for Type 1 and Type 2 DiabetesMany drugs can interfere with Exubera.

28. GLAXO SMITH KLINEFounded in - 2000Revenue- £28.36billion(2009)Net Income - £5.66 billion (2009)Employee’s - 99,000 (2009)Ranked No. 1 in sales

29. MAIN PRODUCTIONS AREAS INCLUDEAsthma Cancer Virus control Mental health Diabetes and Digestive conditions

30. POSITIONING OF MEDICINE FOR DIABETES AVANDIA is the main product for diabetes.Oral Drug.To treat Type-2 diabetes.Increase the risk of Heart attack, Strokes, Fractures, Eye damage.

31. ASTRA ZENECAFounded in - 2000Revenue -$32,804 million(2009) Net Income - $7,544 million(2009)Employee’s - 116,500 (2009)

32. MAIN PRODUCTIONS AREAS INCLUDE Cancer Cardiovascular Gastrointestinal infection Neuroscience Respiratory disorder Inflammation.THEY HAVE NO PRODUCT FOR DIABETES.

33. MAJOR COMPETITORS IN BRAZILAtlanta Pharmaceuticals.Bayer’s Pharmaceuticals.Novartis Pharmaceuticals.Roche Pharmaceuticals.Ache Laboratories Pharmaceuticals.

34. BAYER’S PHARMACEUTICALSFounded in - 1863Revenue - €31.17billion(2009)Net Income - €3.0 billion (2009)Employee’s - 108,400 (2009)

35. MAIN PRODUCTIONS AREAS INCLUDEVeterinary drugs General and specialty medicines Women's health products Over-the-counter drugs Diabetes care

36. PRODUCT FOR DIABETESBayer’s Contour USB Meter for measuring Blood Glucose.Bayer’s Entrust for measuring Blood Glucose.

37. NOVARTIS PHARMACEUTICALSFounded in - 1996Revenue - $44.27billion(2009)Net Income - $8.40 billion (2009)Employee’s - 99,830

38. MAIN PRODUCTIONS AREAS INCLUDEPharmaceuticals Generic drugs Over-the-counter drugs Vaccines Contact lenses

39. POSITIONING FOR DIABETES Novartis resource DiabetishieldA Nutritional drink formulated for Individuals with Diabetes. Added arginine, chromium, and vitamins C and E help to improve insulin sensitivity and aid in blood sugar control.

40. ROCHE PHARMACEUTICALSFounded in - 1896Revenue - CHF 49.05billion(2009)Net Income - CHF 12.28 billion (2009)Employee’s - 81,500 (2009)

41. MAIN PRODUCTIONS AREAS INCLUDEPharmaceuticalsXenical(Obesity) Zenapax(Monoclonal Antibody) Valcyte(Antiviral) Bactrim (Antibiotic) Tamiflu (Antiviral)Diagnostics

42. POSITIONING FOR DIABETES Accu-Chek is the brand of blood sugar -testing device. Include- Accu-Chek Aviva Accu-Chek Compact Plus

43. ACHE LABORATORIES PHARMACEUTICALSFounded in - 1974The best pharmaceutical lab in Brazil.Employee’s - 3,000

44. MISSION, VISION AND VALUESVISION-Be the best pharmaceutical lab in Brazil.

45. Preferred by consumers and health professionals.

46. Promote the health and well-being of the entire population.MISSIONContinuously make available with quality.

47. Creativity and convenience.

48. Innovative and accessible products and services that promote consumer health and well being.

49. Respect to people and the environment.VALUESIntegrity

50. Respect to People

51. Respect to the Environment

52. Enterprising Spirit

53. Innovation

54. Sustainable GrowthCOMPETITORS IN GERMANYBoehringerIngelheimMerck KGaAGenericsPhytomedicinesBayer Schering Pharma

55. BOEHRINGER INGELHEIMFounded in - 1885Revenue - €11.595 billion (2008)Net Income - €1.424 billion (2008)Employee’s - 41,300 (2008)

56. MAIN PRODUCTION AREAS Human Pharmaceuticals Prescription medicines

57. Healthcare productsBiopharmaceuticals ChemicalsAnimal health products

58. POSITIONING FOR DIABETESLINAGLIPTIN is the main product.Effective against Type-II Diabetes.Oral Medicine.Still under trial.

59. MERCK KGAAFounded in - 1668Revenue - €7.747 billion (2009)Operative Income - €620.9 million (2009)Employee’s - 40,507 (2010)

60. MAIN PRODUCTION AREASLiquid crystalsLife science and performance chemicalsOver-the-counter medicinesSmall molecules Biopharmaceuticals

61. POSITIONING FOR DIABETESJANUVIA is drug which works for the management of Type 2 diabetes.Oral Medicine.Side Effects- severe pain in stomach nausea and vomiting, loss of appetite, fast heart rate, fever, sore throat.

62. BAYER SCHERING PHARMAFounded in - 2006Revenue - €10.267 billion (2007)Employee’s- 26,000 (2004)Headquarter - Germany

63. MAIN PRODUCTION AREASGynaecology & AndrologySpecial therapeutics Diagnostical devicesNuclear medicineOncology

64. POSITIONING FOR DIABETESLaunched SciLin a recombinant insulin product, in China.Oral Drug for Adults.

65. COMPETITORS IN INDIARanbaxy (Daiichi)Dr. Reddy’s LaboratoriesCiplaSun PharmaAurobindoPharma

66. RANBAXY (DAIICHI)Founded in - 1961Revenue - US$ 1,405 million (2010)Net Income - US$ 349 million (2010)Employee’s - 1,100 in R & DOperating in over - 125 CountriesMarket Share in India - 4.9%

67. MAIN PRODUCTION AREASCardiovascularCentral Nervous SystemRespiratoryDermatologyOrthopedicsNutritionals Urology

68. POSITIONING FOR DIABETESVOLIX (VOGLIBOSE) is the main product for Treatment Of Diabetes.Help in improving of Postprandial Hyperglycemia in Diabetes Mellitus.Oral Drug.Will Launch anti-diabetic drug ACTOS in the US by 2012.

69. Dr. REDDY’S LABORATORIESFounded in - 1984Revenue - US$ 1.5 billion (2007)Net Income - US$ 216 million (2007)Employee’s - 8,225Major seller in Europe, Canada and Russian. Number one in India in terms of profitability.

72. MAIN PRODUCTION AREASCancerDiabetesCardiovascular disease InflammationBacterial infection

73. POSITIONING FOR DIABETESBALAGLITAZONE is the main product for Diabetes.First lead molecule in anti-diabetic segment.RAGAGLITAZONE is a new product & is more promising.

74. CIPLAFounded in - 1935Revenue - US$ 1.28 billion (2010)Net Income - US$ 245.7 million (2010)Employee’s - 7,0002nd Largest Pharmaceutical Company in India in terms of retail sales.

75. Operating in 170 Countries.

76. MAIN PRODUCTION AREASPharmaceuticalsAnimal Health Care ProductsOTC (Over The Counter) DrugBulk DrugsFlavours& FragrancesAgrochemicals